Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Turner Medical Sciences Long/Short Fund Class C (TMSCX)

11.70
Net Asset Value
-0.26%
1 Day
-8.59%
Year-to-Date
Overall Morningstar Rating
Long/short equity
Style or Category
No Load
Sales Expenses
4.40%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. The fund invests primarily (at least 80% of its net assets) in stocks of companies engaged in the health care sector using a long/short growth strategy in seeking to capture alpha, reduce volatility, and preserve capital in declining markets. Its holdings may generally range from small companies with over $250 million in market capitalization at the time of purchase to larger, established firms in the health care industry. The fund typically holds between 15 and 75 securities long, and between 15 and 75 securities short.

Performance

1 month-5.40% 3 years+9.49%
3 months-9.01% 5 years+5.74%
1 year+0.90% Since inception+6.39%
Data through --

Peer Comparisonvs. Long/short equity

 TMSCXCategory
Performance 5-yr return+5.74%+4.45%
Expense ratio4.40%1.84%
Risk 5 year sharpe ratio--0.44
Net assets$129.5M$297.1M
Average market cap$5.1B$45.8B
Average P/E17.618.3
Portfolio turnover206%206%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyTurner Funds
Fund manager & tenureMichael Tung / 1 Years
Minimal initial investment$2,500.00
Minimum IRA investment$2,000.00

Holdings

Cash47.36%
U.S. stock42.03%
International stock10.48%
Fixed income0.14%
Other0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
PFE Pfizer3.64%
HZNP Horizon Pharma PLC3.49%
TLGT Teligent Inc3.18%
NVS Novartis3.04%
LLY Eli Lilly and Co3.01%
RTRX Retrophin Inc2.83%
-- 2.54%
GSK GlaxoSmithKline2.43%
PRTA Prothena Corporation PLC2.35%
ACHN Achillion Pharmaceuticals Inc2.31%

Partner Offers